GlassScriptPhysician profile
Amber Walls
NPI 1548632524
$11,133.63
in general payments reported to CMS, 2019-2025
48 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,221 · 2022: $2,270 · 2023: $2,495 · 2024: $2,693 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,642.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,574.10 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $896.42 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $887.87 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.38 | 2021-2025 | Jardiance, Jascayd, Ofev |
| Pfizer INC. | $680.03 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $654.31 | 2021-2025 | |
| Abbvie INC. | $562.30 | 2022-2025 | |
| Amgen INC. | $550.55 | 2021-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $481.40 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $479.77 | 2021-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $257.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $254.84 | 2021-2024 | Spravato, Xarelto |
| Viiv Healthcare Company | $253.37 | 2022-2025 | Apretude |
| Amarin Pharma, INC. | $193.37 | 2021 | |
| Merck Sharp & Dohme LLC | $193.10 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $183.08 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $175.71 | 2022-2024 | |
| Shield Therapeutics INC | $167.18 | 2024-2025 | |
| Abbott Laboratories | $161.12 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $139.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $131.65 | 2022 | |
| Paratek Pharmaceuticals, INC. | $123.64 | 2024-2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.18 | 2021-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $110.82 | 2021-2025 | |
| Noven Therapeutics, LLC | $92.97 | 2023 | Secuado |
| Currax Pharmaceuticals LLC | $87.91 | 2022-2023 | Contrave, Nexletol, Nexlizet |
| Vertex Pharmaceuticals Incorporated | $87.27 | 2024-2025 | |
| Dynavax Technologies Corporation | $85.77 | 2022-2025 | Heplisav-B |
| Supernus Pharmaceuticals, INC. | $83.47 | 2022-2023 | Qelbree |
| Corcept Therapeutics | $77.57 | 2024-2025 | Korlym |
| Antares Pharma, INC. | $76.03 | 2021-2024 | Xyosted |
| Gilead Sciences, INC. | $71.91 | 2025 | |
| Eisai INC. | $52.64 | 2022-2024 | |
| Lundbeck LLC | $50.92 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $48.90 | 2024 | Skyclarys |
| Dexcom, INC. | $48.49 | 2022-2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $39.99 | 2022-2023 | Livalo, Seglentis |
| Sumitomo Pharma America, INC. | $37.36 | 2024-2025 | Gemtesa |
| Abiomed | $34.57 | 2025 | |
| Axsome Therapeutics, INC. | $28.24 | 2025 | Auvelity |
| Medtronic, INC. | $26.80 | 2025 | Intellis Adaptivestim |
| Corium, LLC | $24.49 | 2023 | Azstarys |
| Bioventus LLC | $22.53 | 2023 | Durolane |
| Azurity Pharmaceuticals, INC. | $20.73 | 2023 | Edarbi |
| Teva Pharmaceuticals USA, INC. | $20.60 | 2022 | |
| Tolmar, INC. | $19.12 | 2025 | Jatenzo |
| Esperion Therapeutics, INC. | $12.62 | 2021 | |
| Genentech USA, INC. | $7.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.